BLB&B Advisors LLC held its position in Medtronic PLC (NYSE:MDT) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,487 shares of the medical technology company’s stock at the end of the second quarter. BLB&B Advisors LLC’s holdings in Medtronic PLC were worth $1,087,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Jackson Grant Investment Advisers Inc. boosted its position in Medtronic PLC by 0.3% in the first quarter. Jackson Grant Investment Advisers Inc. now owns 2,920 shares of the medical technology company’s stock valued at $235,000 after buying an additional 9 shares during the last quarter. Hudock Capital Group LLC boosted its position in Medtronic PLC by 0.6% in the first quarter. Hudock Capital Group LLC now owns 2,184 shares of the medical technology company’s stock valued at $175,000 after buying an additional 12 shares during the last quarter. Delta Asset Management LLC TN boosted its position in Medtronic PLC by 0.4% in the first quarter. Delta Asset Management LLC TN now owns 3,713 shares of the medical technology company’s stock valued at $299,000 after buying an additional 13 shares during the last quarter. Bollard Group LLC boosted its position in Medtronic PLC by 0.4% in the first quarter. Bollard Group LLC now owns 3,637 shares of the medical technology company’s stock valued at $293,000 after buying an additional 14 shares during the last quarter. Finally, Triangle Securities Wealth Management boosted its position in Medtronic PLC by 0.3% in the second quarter. Triangle Securities Wealth Management now owns 4,396 shares of the medical technology company’s stock valued at $390,000 after buying an additional 15 shares during the last quarter. Hedge funds and other institutional investors own 83.36% of the company’s stock.

Shares of Medtronic PLC (NYSE:MDT) traded down 0.1723% during mid-day trading on Wednesday, hitting $83.6856. The stock had a trading volume of 1,473,891 shares. The firm has a 50 day moving average price of $86.89 and a 200-day moving average price of $82.57. Medtronic PLC has a 12 month low of $69.35 and a 12 month high of $89.72. The stock has a market cap of $113.73 billion, a P/E ratio of 28.9570 and a beta of 1.02.

Medtronic PLC (NYSE:MDT) last posted its quarterly earnings results on Thursday, May 25th. The medical technology company reported $1.33 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.31 by $0.02. Medtronic PLC had a return on equity of 12.72% and a net margin of 13.56%. The business had revenue of $7.92 billion for the quarter, compared to analyst estimates of $7.86 billion. During the same period last year, the company earned $1.27 EPS. Medtronic PLC’s revenue for the quarter was up 4.6% compared to the same quarter last year. On average, equities research analysts forecast that Medtronic PLC will post $4.81 EPS for the current year.

The business also recently declared a quarterly dividend, which was paid on Wednesday, July 26th. Investors of record on Friday, July 7th were given a dividend of $0.46 per share. This represents a $1.84 annualized dividend and a yield of 2.19%. This is a positive change from Medtronic PLC’s previous quarterly dividend of $0.43. The ex-dividend date was Wednesday, July 5th. Medtronic PLC’s dividend payout ratio (DPR) is presently 63.67%.

ILLEGAL ACTIVITY NOTICE: This article was first published by Daily Political and is owned by of Daily Political. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The correct version of this article can be read at https://www.dailypolitical.com/2017/08/09/blbb-advisors-llc-has-1087000-stake-in-medtronic-plc-mdt.html.

Several research firms have weighed in on MDT. UBS AG reiterated a “buy” rating and set a $95.00 price objective (up previously from $94.00) on shares of Medtronic PLC in a research report on Tuesday, May 30th. Jefferies Group LLC reiterated a “buy” rating and set a $103.00 price objective on shares of Medtronic PLC in a research report on Thursday, August 3rd. Barclays PLC reiterated an “overweight” rating and set a $94.00 price objective (up previously from $92.00) on shares of Medtronic PLC in a research report on Sunday, May 28th. CIBC reiterated a “buy” rating on shares of Medtronic PLC in a research report on Friday, May 26th. Finally, Cowen and Company reiterated an “outperform” rating and set a $95.00 price objective (up previously from $86.00) on shares of Medtronic PLC in a research report on Sunday, May 28th. Three research analysts have rated the stock with a sell rating, nine have issued a hold rating and fifteen have given a buy rating to the stock. Medtronic PLC presently has an average rating of “Hold” and a consensus target price of $89.84.

In related news, EVP Bryan C. Hanson sold 12,000 shares of the firm’s stock in a transaction that occurred on Monday, July 17th. The stock was sold at an average price of $88.57, for a total transaction of $1,062,840.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Richard H. Anderson purchased 5,600 shares of Medtronic PLC stock in a transaction that occurred on Wednesday, June 21st. The shares were bought at an average price of $88.90 per share, for a total transaction of $497,840.00. Following the completion of the transaction, the director now owns 71,910 shares in the company, valued at $6,392,799. The disclosure for this purchase can be found here. 0.25% of the stock is owned by company insiders.

About Medtronic PLC

Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT).

Institutional Ownership by Quarter for Medtronic PLC (NYSE:MDT)

Receive News & Ratings for Medtronic PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic PLC and related companies with MarketBeat.com's FREE daily email newsletter.